We studied the effect of a novel purine acyclic nucleoside, 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), on human cytomegalovirus (HCMV) replication. The susceptibility of HCMV to this drug was monitored in cell culture by plaque reduction assay. HCMV replication of various strains was inhibited to the extent of 50%o by 1 to 5 ,uM DHPG. DHPG was highly specific in its anti-HCMV activity, since at concentrations as high as 100 ,uM it did not exert any detectable inhibitory effect on uninfected cell macromolecular synthesis and cell growth. At concentrations of 2 to 4 ,uM, the drug inhibited the synthesis of six virus-specific polypeptides with molecular weights of 200,000 (VP200), 150,000 (VP150), 67,000 (VP67), 54,000 (VP54), 32,000 (VP32), and 27,000 (VP27) up to 96 h after infection. HCMV DNA synthesis was also considerably suppressed at concentrations of 2 to 4 ,M DHPG. Upon removal of the inhibitor, however, viral DNA synthesis resumed and infectious virus reappeared, indicating that this inhibition was a virostatic reversible-type inhibition.
Ideal antiviral chemotherapy should be specific for the inhibition of viral replication with minimum toxicity to the host. Of the existing antiviral compounds, acyclovir (ACV) was discovered to be a potent and selective inhibitor of herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), with little effect on uninfected cells (5) . A virus-encoded thymidine kinase (TK) is required to activate ACV in infected cells (5) . ACV has been found to have limited anti-human cytomegalovirus (HCMV) activity (4, 11, 13) since HCMV does not encode virus-specific TK enzyme in infected cells (6, 16) .
Recently, four companies (Syntex Inc., Biologics Co., Wellcome Research Laboratories, and Merck Sharpe and Dohme Research Laboratories) have independently developed a novel guanosine analog, 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) . Besides its extreme potency against HSV-1 and HSV-2 (1, 3, 12, 14, 15) , DHPG has been demonstrated to effectively inhibit HCMV replication in vitro (14) . In this communication, we report the in vitro anti-HCMV activity of DHPG and its mode of action on viral DNA replication and virus-specific protein synthesis. Our results confirm and extend the observations made by other investigators (14) . Figure 2 shows the inhibition of six virus-specific polypeptides (VP200, VP150, VP67, VP54, VP32, and VP27) by the drug for up to 96 h after infection. However, the expression of VP67 was not completely inhibited. These proteins were detected in non-drug-treated infected cells 48 h after infection. Thus, these polypeptides should be virus-specific late antigens. DISCUSSION A recently developed ACV congener, DHPG, was demonstrated to be an extremely potent antiherpetic compound with low toxicity to normal cells (3, 12, 14, 15) . The modes of action of DHPG and ACV are similar in that the herpes TK specifically phosphorylates each nucleoside and both compounds selectively inhibit viral replication over cell proliferation (1, 3, 5, 12, 14, 15) . It has been observed that ACV and DHPG are totally inactive against HSV mutants which do not induce virus TK in infected cells (3, 5, 14, 15) , indicating that a herpes-encoded TK enzyme is required to activate DHPG as well as ACV in infected cells.
Recently, DHPG was reported to have a marginal activity against Epstein-Barr virus (ID50 = 32 p.M) and to have no activity against HCMV even at a concentration as high as 390 ,uM (15) . In contrast, Smee and colleagues (14) demonstrated that, besides its potency against HSV-1 and HSV-2, DHPG effectively inhibited a strain of HCMV (AD169) by 50o at 7 AM. In addition, at concentrations as low as 0.05 ,uM, DHPG reduced Epstein-Barr virus genome numbers in P3HR-1 cells by 50% (J. S. Pagano, J. W. Sixbey, and J.-C. Lin, J. Antimicrob. Chemother., in press; J.-C. Lin, M. C. Smith, and J. S. Pagano, submitted for publication). In the present investigation, we also demonstrate that DHPG is a potent and selective anti-HCMV agent with viral ID50s ranging from 1 to 5 ,uM, depending upon the virus strain used ( Table 1) .
The ID50 for cell growth was 300 ,uM. Our data are in reasonable agreement with the data reported by Smee and co-workers (14) . The discrepancy between positive and negative results of anti-Epstein-Barr virus and anti-CMV activities of DHPG as reported by others may be due to the use of different methodologies. Smith et al. (15) examined the effect of DHPG on the expression of virus-specific antigens which were expressed despite the inhibition of viral DNA synthesis, whereas in this study and in the Quantitation of viral DNA synthesis, using cRNA-DNA hybridization, demonstrated a dramatic inhibition of HCMV DNA replication at 2 to 4 ,M DHPG (Fig. 1) . At these drug concentrations, the synthesis of five virus-specific late polypeptides (VP200, VP150, VP54, VP32, and VP27) was markedly inhibited (Fig. 2) . The additional virus-specific polypeptide (VP67) which was inhibited substantially at an early stage of infection accumulated to a certain extent at a late stage of infection (Fig. 2) . The resumption of VP67 (Fig. 2) and a gradual and low-level increase in the concentration of viral DNA sequences (Fig. 1) at a later stage of drug treatment may be due to degradation of the drug in cell cultures. After removal of the inhibitor from cell cultures, viral DNA synthesis resumed ( Fig. 1) and infectious virus became detectable. These phenomena suggest that the inhibitory effect by DHPG of HCMV replication was a virostatic reversible type of inhibition.
In spite of the structural resemblance of DHPG to ACV, the therapeutic index of DHPG against HCMV is much higher in cell culture than that of ACV. The broader antiviral spectrum, greater inhibitory effect, lower cytotoxicity, and higher solubility of DHPG (14, 15) compared with other existing antiherpetic compounds make DHPG a potential candidate for antiherpes chemotherapy.
The ineffectiveness of DHPG on TK-mutants of HSV-1 and HSV-2 (3, 14, 15) suggests the importance of the virus-encoded TK enzyme in the molecular action of this drug. Since HCMV does not encode a virus-specific TK, the mechanism by which DHPG exhibits the inhibitory effect against HCMV in vitro is still unclear. It is one of our mijor interests to study the possible role of virus-stimulated cellular TK enzyme (6, 16) in regard to the anti-HCMV activity of DHPG.
